Clinical Trial Update: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy results for MIS416 in secondary progressive multiple sclerosis have been reported. The study was sponsored by Innate Immunotherapeut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• MIS416

Snippet

Sponsor: Innate Immunotherapeutics | Conditions: Secondary Progressive Multiple Sclerosis | Phase 2 | Status: COMPLETED